DHX9: A Potential Drug Target and Biomarker (G1660)

Target Name: DHX9

NCBI ID: G1660

DHX9

DHX9: A Potential Drug Target and Biomarker

Dihu DHX9, also known as DHX9L, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases.

The DHX9 molecule is a part of the heat shock factor family, which are known to play a crucial role in regulating gene expression and cellular processes during times of stress, such as increased temperature or the presence of toxins. DHX9 is a 24-nt RNA molecule that consists of 19 exons and an unspecified number of introns. It is expressed in various tissues and has been shown to play a role in regulating gene expression and cell proliferation.

One of the key features of DHX9 is its ability to interact with various proteins, including transcription factors, to enhance their transcriptional activity. This interaction between DHX9 and transcription factors has led to the identification of DHX9 as a potential drug target. Researchers have shown that inhibiting DHX9's activity can lead to reduced gene expression and can inhibit the growth and survival of cancer cells, neurodegenerative disease cells, and other infected or damaged cells.

Another potential mechanism by which DHX9 may be a drug target is its role in the development of psychiatric disorders. Studies have shown that DHX9 is involved in the regulation of gene expression in the brain and that it is implicated in the development of various psychiatric disorders, including depression, anxiety, and schizophrenia. By targeting DHX9, researchers may be able to develop new treatments for these disorders.

In addition to its potential as a drug target, DHX9 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be regulated in a variety of tissues and conditions, including cancer, neurodegenerative diseases, and psychiatric disorders. This makes it an attractive candidate for use as a diagnostic or predictive marker for these diseases.

One of the challenges in studying DHX9 as a potential drug target is its complex structure and function. While researchers have identified its unique properties, they are still working to fully understand its role in cellular processes and its potential interactions with other molecules. This lack of understanding may make it difficult to design effective treatments that target DHX9 specifically.

Despite these challenges, the potential of DHX9 as a drug target and biomarker is significant. Its unique properties and its involvement in various diseases make it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases. As research continues to advance, it is likely that DHX9 will become a valuable tool for the development of new treatments for a variety of disorders.

Protein Name: DExH-box Helicase 9

Functions: Multifunctional ATP-dependent nucleic acid helicase that unwinds DNA and RNA in a 3' to 5' direction and that plays important roles in many processes, such as DNA replication, transcriptional activation, post-transcriptional RNA regulation, mRNA translation and RNA-mediated gene silencing (PubMed:9111062, PubMed:11416126, PubMed:12711669, PubMed:15355351, PubMed:16680162, PubMed:17531811, PubMed:20669935, PubMed:21561811, PubMed:24049074, PubMed:25062910, PubMed:24990949, PubMed:28221134). Requires a 3'-single-stranded tail as entry site for acid nuclei unwinding activities as well as the binding and hydrolyzing of any of the four ribo- or deoxyribo-nucleotide triphosphates (NTPs) (PubMed:1537828). Unwinds numerous nucleic acid substrates such as double-stranded (ds) DNA and RNA, DNA:RNA hybrids, DNA and RNA forks composed of either partially complementary DNA duplexes or DNA:RNA hybrids, respectively, and also DNA and RNA displacement loops (D- and R-loops), triplex-helical DNA (H-DNA) structure and DNA and RNA-based G-quadruplexes (PubMed:20669935, PubMed:21561811, PubMed:24049074). Binds dsDNA, single-stranded DNA (ssDNA), dsRNA, ssRNA and poly(A)-containing RNA (PubMed:9111062, PubMed:10198287). Binds also to circular dsDNA or dsRNA of either linear and/or circular forms and stimulates the relaxation of supercoiled DNAs catalyzed by topoisomerase TOP2A (PubMed:12711669). Plays a role in DNA replication at origins of replication and cell cycle progression (PubMed:24990949). Plays a role as a transcriptional coactivator acting as a bridging factor between polymerase II holoenzyme and transcription factors or cofactors, such as BRCA1, CREBBP, RELA and SMN1 (PubMed:11149922, PubMed:9323138, PubMed:9662397, PubMed:11038348, PubMed:11416126, PubMed:15355351, PubMed:28221134). Binds to the CDKN2A promoter (PubMed:11038348). Plays several roles in post-transcriptional regulation of gene expression (PubMed:28221134, PubMed:28355180). In cooperation with NUP98, promotes pre-mRNA alternative splicing activities of a subset of genes (PubMed:11402034, PubMed:16680162, PubMed:28221134, PubMed:28355180). As component of a large PER complex, is involved in the negative regulation of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms (By similarity). Acts also as a nuclear resolvase that is able to bind and neutralize harmful massive secondary double-stranded RNA structures formed by inverted-repeat Alu retrotransposon elements that are inserted and transcribed as parts of genes during the process of gene transposition (PubMed:28355180). Involved in the positive regulation of nuclear export of constitutive transport element (CTE)-containing unspliced mRNA (PubMed:9162007, PubMed:10924507, PubMed:11402034). Component of the coding region determinant (CRD)-mediated complex that promotes cytoplasmic MYC mRNA stability (PubMed:19029303). Plays a role in mRNA translation (PubMed:28355180). Positively regulates translation of selected mRNAs through its binding to post-transcriptional control element (PCE) in the 5'-untranslated region (UTR) (PubMed:16680162). Involved with LARP6 in the translation stimulation of type I collagen mRNAs for CO1A1 and CO1A2 through binding of a specific stem-loop structure in their 5'-UTRs (PubMed:22190748). Stimulates LIN28A-dependent mRNA translation probably by facilitating ribonucleoprotein remodeling during the process of translation (PubMed:21247876). Plays also a role as a small interfering (siRNA)-loading factor involved in the RNA-induced silencing complex (RISC) loading complex (RLC) assembly, and hence functions in the RISC-mediated gene silencing process (PubMed:17531811). Binds preferentially to short double-stranded RNA, such as those produced during rotavirus intestinal infection (PubMed:28636595). This interaction may mediate NLRP9 inflammasome activation and trigger inflammatory response, including IL18 release and pyroptosis (PubMed:28636595). Finally, mediates the attachment of heterogeneous nuclear ribonucleoproteins (hnRNPs) to actin filaments in the nucleus (PubMed:11687588)

The "DHX9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHX9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets